Want to join the conversation?
$VRTX reported total CF product revenues of approx. $426MM in 2Q16 versus $155MM in 2Q15. Orkambi drug sales were $245MM. Kalydeco drug sales were up $25MM to $108MM. Operating expenses rose in 2Q16, due to increased costs related to the progression of CF pipeline and increased investments in global commercial support for the launch of Orkambi.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?